{'52WeekChange': -0.16831684,
 'SandP52WeekChange': None,
 'address1': '4400 Route 9 South',
 'address2': 'Suite 3100',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.6,
 'askSize': 900,
 'averageDailyVolume10Day': 171912,
 'averageVolume': 270798,
 'averageVolume10days': 171912,
 'beta': 0.707075,
 'beta3Year': None,
 'bid': 1.59,
 'bidSize': 2900,
 'bookValue': 0.048,
 'category': None,
 'circulatingSupply': None,
 'city': 'Freehold',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.68,
 'dayLow': 1.56,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.688,
 'enterpriseToRevenue': 85.365,
 'enterpriseValue': 128643904,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '732 780 5600',
 'fiftyDayAverage': 1.7027143,
 'fiftyTwoWeekHigh': 2.65,
 'fiftyTwoWeekLow': 0.5,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25062656,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 7,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.68584,
 'heldPercentInstitutions': 0.03458,
 'industry': 'Medical Care Facilities',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/avalon-globocare.com',
 'longBusinessSummary': 'Avalon GloboCare Corp., together with its '
                        'subsidiaries, owns and operates commercial real '
                        'estate properties in the United States and the '
                        "People's Republic of China. The company offers "
                        'medical related consulting services, including '
                        'research studies, executive education, daily online '
                        'executive briefings, tailored expert advisory '
                        'services, and consulting and management services in '
                        'the areas of immunotherapy and second '
                        'opinion/referral services. It also develops Avalon '
                        'Cell and Avalon Rehab platforms that cover the areas '
                        'of regenerative medicine, cell-based immunotherapy, '
                        'and exosome technology. In addition, the company '
                        'develops proprietary diagnostic and therapeutic '
                        'products leveraging exosome technology; and provides '
                        'development services for hospitals. The company has a '
                        'strategic partnership with Weill Cornell Medical '
                        'College to co-develop bio-production and '
                        'standardization procedures for chimeric antigen '
                        'receptor (CAR)-T Therapy; GensKey Medical Technology '
                        'Co. Ltd. to co-develop and commercialize '
                        'point-of-care, rapid detection antibody tests to '
                        'identify whether a patient has been exposed to and '
                        'has developed antibodies against SARS-CoV-2; GE '
                        'Healthcare to enhance standardized automation and '
                        'bio-production for cellular medicines; and '
                        'HydroPeptide, LLC to co-develop and commercialize '
                        'various clinical-grade, exosome-based cosmeceutical '
                        'and orthopedic products, as well as research '
                        'agreement with Massachusetts Institute of Technology '
                        'to develop CAR technology. Avalon GloboCare Corp. is '
                        'headquartered in Freehold, New Jersey.',
 'longName': 'Avalon GloboCare Corp.',
 'market': 'us_market',
 'marketCap': 126190032,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_402754209',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -16935126,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.68,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '646 762 4517',
 'previousClose': 1.68,
 'priceHint': 4,
 'priceToBook': 33.125,
 'priceToSalesTrailing12Months': 83.73703,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.68,
 'regularMarketDayLow': 1.56,
 'regularMarketOpen': 1.68,
 'regularMarketPreviousClose': 1.68,
 'regularMarketPrice': 1.68,
 'regularMarketVolume': 286454,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 79364800,
 'sharesPercentSharesOut': 0.0123000005,
 'sharesShort': 972992,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 840950,
 'shortName': 'Avalon GloboCare Corp.',
 'shortPercentOfFloat': 0.0376,
 'shortRatio': 3.5,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'AVCO',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.223,
 'twoHundredDayAverage': 1.5856906,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'aba8052b-63b6-3c4f-a2c0-58324914fd28',
 'volume': 286454,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.avalon-globocare.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '07728'}